Journal articles
Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone
Abstract : Recently, phase III trials assessed a new combination of lenalidomide, bortezomib, and dexamethasone (RVD) in induction therapy in transplantation‐eligible multiple myeloma (MM) patients, before consolidation with RVD and lenalidomide maintenance. We present a retrospective study evaluating this approach with patients from the real life.
Cited literature [29 references]
https://hal-amu.archives-ouvertes.fr/hal-02267221
Contributor : Lionel Spinelli Connect in order to contact the contributor
Submitted on : Friday, October 18, 2019 - 9:52:29 AM
Last modification on : Thursday, January 6, 2022 - 3:58:01 PM
Long-term archiving on: : Sunday, January 19, 2020 - 1:05:14 PM
Contributor : Lionel Spinelli Connect in order to contact the contributor
Submitted on : Friday, October 18, 2019 - 9:52:29 AM
Last modification on : Thursday, January 6, 2022 - 3:58:01 PM
Long-term archiving on: : Sunday, January 19, 2020 - 1:05:14 PM
Files
Revised Manuscript VRD EJH Fin...
Files produced by the author(s)